Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07249346 · ClinicalTrials.gov registry record · Phase 2
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
A Phase 2 study of Leukemia and Chronic Myelomonocytic Leukemia, sponsored by Hannah Choe, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT07249346 is a Phase 2 study of Leukemia and Chronic Myelomonocytic Leukemia that is actively recruiting participants, run by Hannah Choe, MD. The registered enrollment target is 124 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07249346, a Phase 2 study of Leukemia and Chronic Myelomonocytic Leukemia, is actively recruiting participants, sponsored by Hannah Choe, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Ruxolitinib
- DRUG Tacrolimus
- DRUG Myeloablative conditioning regimen
- PROCEDURE Hematopoietic Stem Cell Transplantation
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07249346
The ClinicalTrials.gov registry entry for NCT07249346 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (74% lower). The listed sponsor is Hannah Choe, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07249346 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07249346 about?
NCT07249346 is a clinical study titled "Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation". This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
What is the current status of trial NCT07249346?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2026-06-01. Estimated completion is 2027-06-01.
What conditions does trial NCT07249346 study?
This clinical trial studies the following conditions: Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplasia.
What interventions are being tested in trial NCT07249346?
The interventions under investigation include: Cyclophosphamide (DRUG), Ruxolitinib (DRUG), Tacrolimus (DRUG), Myeloablative conditioning regimen (DRUG), Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT07249346?
This trial is sponsored by Hannah Choe, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07249346 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
-
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.